Long-term Effect of Lanthanum Carbonate on Bone

Shire34 enrolled

Overview

Patients enrolled in a previous study (SPD405-309), who were exposed to lanthanum carbonate (Fosrenol), were eligible to continue on any prescribed treatment for hyperphosphatemia, including lanthanum carbonate (Fosrenol), for an additional 5 years. Patients were being observed for any bone adverse events or other serious adverse events, as well as the collection of mortality data.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hyperphosphatemia

Interventions

Lanthanum carbonateDRUG

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Any patient who had exposure to lanthanum carbonate in SPD405-309

Locations (19)

Imperial care Dialysis Center

Lynwood, California, United States

Barnett Research and Communications Medical Group

Torrance, California, United States

Outcomes

Primary Outcomes

Number of Study-emergent Bone-related Adverse Events (AEs)

Time frame: 5 years

Secondary Outcomes

Number of Study-emergent Deaths

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.